Celgene & Acceleron Submit BLA For Luspatercept To The FDA
Zacks Investment Research | Apr 08, 2019 06:11AM ET
Celgene Corporation (NASDAQ:CELG) announced that it has submitted a Biologics License Application (BLA) for pipeline candidate, luspatercept, a first-in-class erythroid maturation agent (EMA) that regulates late-stage red blood cell (RBC) maturation.
The company is developing luspatercept in collaboration with partner Acceleron Pharma Inc. (NASDAQ:XLRN) .
The BLA is seeking FDA approval of luspatercept for the treatment of adult patients with very low to intermediate risk myelodysplastic syndromes (MDS)-associated anemia, who have ring sideroblasts and require RBC transfusions, and adult patients with beta-thalassemia-associated anemia, who require RBC transfusions.
The BLA was submitted on the basis of safety and efficacy results from the phase III studies, MEDALIST and BELIEVE.
Both the companies plan to submit a marketing application to the European Medicines Agency in the second quarter of 2019.
Meanwhile, the candidate is also being evaluated in phase III trial, COMMANDS, for the treatment of erythropoiesis-stimulating agent (ESA) naïve, lower-risk MDS patients. Luspatercept is also being evaluated in the BEYOND phase II trial in non-transfusion-dependent beta-thalassemia, and a phase II trial in myelofibrosis.
Celgene’s stock has gained 9.3% in the past six months, against the industry ’s decline of 6.2%.
Meanwhile, the company has been in the news lately due to a merger agreement with Bristol-Myers Squibb Company (NYSE:BMY) announced earlier this year. Per the deal, Bristol-Myers will acquire Celgene for a whopping $74 billion. The company’s shareholders will receive $50 plus one share of Bristol-Myers and one tradeable Contingent Value Right (CVR), which will entitle the holder to receive a cash payment of $9.00 upon the receipt of FDA approval of three products in its pipeline — ozanimod, liso-cel and bb2121 — within specified time periods.
The company also has a co-development and co-promotion agreement with bluebird bio, Inc. (NASDAQ:BLUE) for bb2121, an experimental anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell therapy, for the potential treatment of patients with relapsed/refractory multiple myeloma in the United States. The acquisition of Juno Therapeutics has added liso-cel to Celgene’s lymphoma pipeline.
Zacks Rank
Get The News You Want
Celgene currently carries a Zacks Rank #3 (Hold). You can see .
Is Your Investment Advisor Fumbling Your Financial Future?
See how you can more effectively safeguard your retirement with a new Special Report, “4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future.”
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.